OLMA Olema Oncology
Price Chart
Executive Summary
Olema Oncology announced a clinical trial collaboration with Bayer to evaluate its KAT6 inhibitor OP-3136 in combination with darolutamide for metastatic castration-resistant prostate cancer (mCRPC). The Phase 1b/2 study will enroll approximately 36 patients and is expected to start in H2 2026. This is the first clinical collaboration for OP-3136, but the deal is non-financial (Bayer supplies drug, Olema runs the study) and the stock has historically declined on neutral news, with a 0% win rate at T+20 across prior reports.
Actionable Insight
This is a modest pipeline-expansion event for a clinical-stage biotech with no revenue. The collaboration validates OP-3136's combinability but carries no near-term financial catalyst. Watch for ASCO data on May 30, 2026, which could provide the first clinical proof-of-concept for OP-3136. Historical pattern of negative drift on OLMA neutral news suggests caution.
Key Facts
- Olema and Bayer entered a clinical trial collaboration for OP-3136 (KAT6 inhibitor) + darolutamide in mCRPC.
- Phase 1b/2 study will enroll ~36 patients; initiation expected in H2 2026.
- Bayer supplies darolutamide; Olema leads the study and retains full global commercial rights to OP-3136.
- Initial Phase 1 monotherapy data for OP-3136 to be presented at ASCO on May 30, 2026.
- No upfront or milestone payments disclosed; deal is a drug-supply collaboration only.
- Historical OLMA reports show 0% win rate at T+20 (n=4 settled), with average T+20 return of -21.87%.
Financial Impact
No financial terms disclosed; Bayer provides darolutamide at no cost; Olema bears study costs.
Risk Factors
- Phase 1b/2 study may fail to show efficacy or safety in mCRPC.
- No financial terms disclosed — deal provides no capital infusion.
- Historical OLMA filings have consistently underperformed at T+20 (avg -21.87%).
- OP-3136 is early-stage (Phase 1); clinical and regulatory risks are high.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300930 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
14d ago
|
8-K
| $13.55 $12.71 | ▼ −6.20% | ▼ −7.28% | $9.96 (−26.49%) |
|
May 26, 2026
14d ago
|
Press Release
| $13.55 $10.69 | ▼ −21.11% | ▼ −22.32% | $9.96 (−26.49%) |
|
May 21, 2026
19d ago
|
8-K
| $13.68 $12.71 | ▼ −7.09% | ▼ −8.75% | $9.96 (−27.19%) |
|
May 21, 2026
19d ago
|
Press Release
| $13.68 $12.71 | ▼ −7.09% | ▼ −8.77% | $9.96 (−27.19%) |
|
May 12, 2026
28d ago
|
8-K
| $13.97 $12.90 | ▼ −7.66% | ▼ −7.74% | $9.96 (−28.70%) |
|
May 12, 2026
28d ago
|
Press Release
| $13.97 $12.90 | ▼ −7.66% | ▼ −7.74% | $9.96 (−28.70%) |
|
Apr 29, 2026
5w ago
|
DEFA14A
| $14.41 $15.13 | ▲ +5.00% | ▲ +3.27% | $9.96 (−30.88%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $16.24 $14.24 | ▼ −12.32% | ▼ −12.37% | $9.96 (−38.67%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $16.58 $15.29 | ▼ −7.78% | ▼ −8.69% | $9.96 (−39.93%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $16.60 $13.97 | ▼ −15.84% | ▼ −13.80% | $9.96 (−40.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access